Early Gestational Diabetes Mellitus: A Need for Better Understanding and Wise Navigation
Abstract
Early gestational diabetes mellitus (eGDM) is a condition identified during early pregnancy, characterized by glucose levels that are neither normal nor high enough to meet the criteria for overt diabetes. eGDM is associated with adverse pregnancy and postpartum outcomes, but owing to its heterogeneity, management remains challenging. Women with eGDM can be categorized into distinct phenotypes: mild, moderate, and severe, based on glycemic levels, response to behavioral interventions, and associated risk factors. Additionally, some women with eGDM regress to normoglycemia, while others with early normoglycemia may develop gestational diabetes later ("potential GDM"). Precision medicine offers a tailored approach to managing eGDM, emphasizing individualized treatment plans to optimize outcomes and minimize harm. Future research should focus on refining diagnostic criteria, identifying phenotypes early, and implementing personalized management strategies. This commentary highlights the need for a nuanced understanding of eGDM to improve maternal and neonatal health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.